India's Pharma Sector Shifts from Generics to Innovation-Driven Growth

India's pharmaceutical sector is transitioning into a phase of capability-led and innovation-driven growth. While large-scale manufacturing remains the foundation of its global relevance, the industry is increasingly strengthening its position across research, advanced therapies and integrated global operations.

The Indian pharmaceutical industry was valued at Rs. 5.41 lakh crore (US$ 60 billion) in 2025 and is estimated to reach Rs. 11.73 lakh crore (US$ 130 billion) by 2030. This growth was driven by a balanced contribution from both exports and domestic consumption, rising life expectancy, increasing prevalence of non-communicable diseases such as diabetes and cardiovascular disorders, and improved access to healthcare services.

India's pharmaceutical exports stood at Rs. 2.71 lakh crore (US$ 30.47 billion) in FY25, registering a growth of 9.4% over the previous year supported by recovery in regulated markets, easing pricing pressures and higher approvals for complex generics.

India is the third-largest pharmaceutical producer globally by volume, a position built on decades of scale, regulatory alignment and cost competitiveness. Accounting for around 20% of global generic drug supply by volume, the country continues to play an important role in expanding access to affordable treatments, particularly across emerging and low-income markets.

The industry has a deep and diversified base, comprising more than 3,000 pharmaceutical companies, over 10,500 manufacturing units, and more than 60,000 generic brands across nearly 60 therapeutic areas. A key competitive advantage is strong compliance with global quality standards. India hosts the largest number of US Food and Drug Administration (USFDA)-approved manufacturing facilities outside the United States, enabling reliable access to highly regulated markets. As a result, over 60% of India's pharmaceutical exports are directed to stringent regulatory destinations, underscoring international confidence in India's manufacturing ecosystem.

Indian pharmaceutical companies are increasingly redirecting capital and research efforts towards segments that require greater scientific depth and regulatory sophistication. Complex generics, biosimilars and biologics are becoming priority areas, especially in therapeutic categories such as oncology, immunology and chronic diseases. These segments are characterised by longer development timelines, higher entry barriers and specialised manufacturing capabilities.

Alongside this shift, India has strengthened its position in contract research, development and manufacturing organisation (CRDMO) services. Indian CRDMO players are engaging earlier in the global drug development lifecycle, supporting clinical research, process optimisation and scale-up manufacturing. This earlier involvement enables companies to build deeper technical expertise while aligning more closely with global innovation pipelines.

India's pharmaceutical industry continues to demonstrate strengthening profitability and solid financial health, reflecting the sector's ability to adapt to changing cost structures and evolving market demand. An assessment of the top 50 listed and unlisted pharmaceutical companies indicates a steady improvement in operating performance following a temporary cost-led moderation in FY23. By FY25, the sector's profit before interest, lease, depreciation and tax (PBILDT) margin had improved to approximately 23.40%, supported by easing raw material and freight costs, improved operating leverage and a favourable shift towards higher-value products. The growing contribution from complex generics, speciality formulations and contract research and manufacturing services (CRAMS) is expected to support further margin expansion in upcoming years.

India's global pharmaceutical footprint extends to more than 200 countries, spanning regulated, semi-regulated and emerging markets. This reach is underpinned by long-term investments in quality systems, inspection readiness and compliance with multiple international regulatory frameworks.

The industry now confronts a defining imperative: to recalibrate its trajectory from a globally acknowledged generics powerhouse to a crucible of next-generation innovation—where ambition must match capability and vision must outpace restrictions. The idea that India will have 100 novel therapeutic agents by 2047, marking 100 years of India's independence, sets the tone for the future.

India has made significant progress, particularly in small-molecule chemistry. Three major arms are expected to power the biopharma sector: manufacturing and reinforcing India's role as the Pharmacy of the World; the innovation trajectory, where the Indian biopharma industry will bring new molecules and biologics to the world; and the talent ecosystem, where India will emerge as a global innovation and R&D powerhouse.

Ten years ago, there was limited focus on global capability centres. Today, however, the talent landscape has pushed the world to think differently. The focus has now shifted towards moving up the value chain and deriving maximum value from India's talent ecosystem. India has very strong talent in the STEM areas, presenting a unique and formidable combination of medical IT talent, biologists, medical professionals, and biochemists.